FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus
Executive Summary
Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the drug and biologic review centers intact but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.